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Abstract
Background: Biologic disease-modifying antirheumatic drugs (bDMARDs) are important options for managing
rheumatoid arthritis (RA). Once patients achieve disease control, clinicians may consider dose reduction or withdrawal
of the bDMARD. Results from published studies indicate that some patients will maintain remission; however, others
will flare. We analyzed data from three etanercept down-titration studies in patients with RA to determine what extent
of remission provides the greatest predictability of maintaining remission following dose reduction or discontinuation.
Methods: Patients with moderate to severe RA from the PRESERVE, PRIZE, and Treat-to-Target (T2T) randomized
controlled trials were included. We determined the proportion of patients achieving remission with etanercept at the
last time point in the induction period, and sustained remission (last two time points), according to the Disease Activity
Score 28-joints (DAS28), the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR)
Boolean criteria, and the clinical disease activity index (CDAI). We also calculated the proportion achieving DAS28 deep
remission (DAS28≤ 1.98), sustained deep remission (last two time points), and low disease activity (LDA), and LDA
according to the CDAI. Then, we evaluated whether they maintained remission or LDA following etanercept dose
reduction or withdrawal.
Results: Patients achieving sustained and/or deep remission were more likely than patients achieving remission or LDA
to maintain remission/LDA after etanercept dose reduction or withdrawal. In PRESERVE, the proportions of patients
with DAS28 sustained deep remission, deep remission, sustained remission, remission, and LDA who maintained
remission following etanercept dose reduction were 81%, 67%, 58%, 56%, and 36%, respectively, P < 0.001 for trend. In
PRESERVE, this trend was significant when etanercept was discontinued and when ACR/EULAR Boolean and CDAI
remission criteria were used. Although some sample sizes were small, the PRIZE and T2T studies also demonstrated
response trends according to ACR/EULAR Boolean and CDAI remission criteria, and T2T demonstrated response trends
according to DAS28.
Conclusions: These results suggest that patients achieving disease control according to a stringent definition, such as
sustained ACR/EULAR Boolean or CDAI remission, or a new definition of sustained deep remission by DAS28, have a
higher probability of remaining in remission or LDA following etanercept dose reduction or withdrawal.
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Background
Treatment guidelines for rheumatoid arthritis (RA) rec-
ommend intensive therapy targeting clinical remission
early in the disease course, when patients have a higher
likelihood of responding to treatment [1–5]. This treat-
ment target has been shown to correlate with better
patient-reported outcomes, greater productivity, and
lower overall healthcare costs than achieving low disease
activity (LDA) [6, 7].
Biologic disease-modifying antirheumatic drugs
(bDMARDs) are important therapeutic options in this
treat-to-target strategy. However, once patients achieve
disease control, clinicians may consider dose reduction
or withdrawal of the bDMARD out of concerns for in-
fection risk, dose-dependent adverse events, or treat-
ment cost [8, 9]. As noted in review articles, studies
evaluating down-titration of bDMARDs have used vari-
ous protocols with respect to baseline disease activity
and the length of time that RA symptoms were under
control before dose reduction or withdrawal of the
bDMARD [8–16]. For example, studies have required
patients to have LDA according to Disease Activity
Score 28-joint count (DAS28 ≤ 3.2) for 6 months [17, 18]
or DAS28 remission (DAS28 < 2.6) for 6 months [19, 20]
or 12 months [21], LDA according to DAS28 or clinician
judgment for 3 months [22, 23], moderate to good Euro-
pean League Against Rheumatism (EULAR) response at
month 6 [24], or remission according to the clinical dis-
ease activity index (CDAI) at month 6 [25].
Published success rates following bDMARD dose reduc-
tion or withdrawal vary widely; in many studies, approxi-
mately 40–60% of patients were able to maintain
remission or LDA, while the remaining patients experi-
enced a flare [8–16]. A higher percentage of patients tend
to flare if the bDMARD is withdrawn rather than de-
creased in dose [1, 8–11, 13].
According to treatment guidelines issued by EULAR, the
Asia Pacific League of Associations for Rheumatology
(APLAR), and the American College of Rheumatology
(ACR), clinicians may consider tapering the bDMARD
when a patient is in persistent remission [1–3]. Unfortu-
nately, it is not possible to predict with 100% certainty
which patients will maintain remission following dose re-
duction or withdrawal. This is an ongoing area of research;
one study with a published protocol, PREDICTRA, is
evaluating which disease and patient characteristics may be
useful in predicting the outcome of tapering a bDMARD
[26]. Evidence from published studies to date suggests that
predictors for successful tapering include early RA, remis-
sion duration of at least 6months, and certain clinical signs
such as normal levels of inflammatory markers and/or ab-
sence of synovitis on ultrasound [8, 27]. One study that
evaluated the relationship between psychological factors
and flare with dose decrease found that baseline scores on
the 36-Item Short Form Survey Mental Health component
and the DAS28 were significant predictors of flare [28].
Analyses from two open-label, nonrandomized clinical
studies (RRR and HONOR) evaluated whether achieving
DAS28 remission according to a lower cut-off value than
2.6 (referred to as deep remission) would enable more
patients to maintain DAS28 remission or LDA following
bDMARD discontinuation [29, 30]. In the RRR trial (n =
102 patients), the significant DAS28 cut-off point was
determined to be < 2.225; in the HONOR trial (n = 52
patients), it was 1.98 [29, 30].
However, measurement of remission with the DAS28
has been criticized since patients can achieve DAS28 re-
mission but still have active disease, such as tender and
swollen joints [31]. Additionally, studies have shown that
if the DAS28 cut-points are used with therapies that dir-
ectly affect the acute-phase response, such as interleukin
(IL)-6 inhibitors or Janus kinase (JAK) inhibitors, signifi-
cant residual disease activity is likely to remain [32–34].
This is the case even if the more stringent remission
cut-points of DAS28 (calculated using C-reactive protein
[CRP]) < 1.9 and DAS28 (calculated using erythrocyte
sedimentation rate [ESR]) < 2.2 are used [32, 35]. There-
fore, alternative outcome measures, such as the ACR/
EULAR index-based or Boolean remission criteria, the
CDAI, or the Simplified Disease Activity Index (SDAI),
should also be considered when evaluating predictors
for maintaining remission following bDMARD dose re-
duction or discontinuation.
Based on results from the literature, we hypothesized
that achieving sustained remission (ACR/EULAR Bool-
ean or CDAI remission criteria) or sustained deep remis-
sion (DAS28 remission criteria) will increase the
likelihood of maintaining remission or LDA following
dose reduction or discontinuation of bDMARD therapy.
We conducted a post hoc analysis of data from three
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etanercept down-titration studies in patients with RA to
determine what extent of remission will provide the
greatest predictability of maintaining remission following
dose reduction or discontinuation. The objectives of this
analysis were to (1) compare baseline characteristics of
patients who achieved sustained deep remission, deep
remission, sustained remission, remission, and LDA with
full-dose etanercept therapy; (2) determine if the extent
of the initial response was predictive of the likelihood of
maintaining remission or LDA after the etanercept dose
was decreased or discontinued; and (3) compare rates of
remission and LDA measured according to the DAS28
criteria, rates of remission measured according to the
ACR/EULAR Boolean criteria, and rates of remission
and LDA measured according to the CDAI criteria.
Methods
This analysis included patients with RA from three ran-
domized, controlled clinical trials (PRESERVE, PRIZE,
and Treat-to-Target [T2T]) that consisted of an open-
label induction period with etanercept 50 mg weekly
(period 1) followed by a double-blind maintenance, re-
duction, or withdrawal period (period 2) [17, 36, 37].
The populations differed among the studies, the patients
in PRESERVE had moderate RA disease activity and a
mean disease duration of 6.9 years, and the patients in
PRIZE and T2T had moderate to high (“moderate-to-se-
vere”) RA disease activity and mean disease durations of
6.5 months and 8.0 years, respectively [17, 36]. Add-
itional details of the study designs are presented in
Table 1. Patients were included in this analysis if they
completed period 1 and were randomized into period 2.
The three studies were conducted according to the
International Conference on Harmonization guidelines
for Good Clinical Practice as well as the ethical princi-
ples of the Declaration of Helsinki. All patients provided
informed consent prior to enrolment, and the institu-
tional review board or independent ethics committee at
each participating center reviewed and approved the
study protocol and consent forms (see “Acknowledg-
ments” for details).
For all treatment groups in the PRESERVE, PRIZE,
and T2T studies, clinical response at the last time point
in period 1 was determined according to three different
remission criteria: DAS28, ACR/EULAR Boolean, and
CDAI. Sustained responses were measured at the last
two time points in period 1, which were as follows: PRE-
SERVE—weeks 28 and 36; PRIZE—weeks 39 and 52;
and T2T—weeks 16 and 24. In each study, DAS28 was
calculated using ESR [38].
Specifically, the following responses, in order of dis-
ease activity, were measured at the end of period 1:
 DAS28 remission criteria [38]:
 Sustained deep remission (deep remission at the
last two time points, with deep remission defined
as DAS28 ≤ 1.98) [30]
 Deep remission
 Sustained remission (remission at the last two
time points, with remission defined as DAS28
> 1.98 to < 2.6)
 Remission
 LDA (DAS28 ≥ 2.6 to < 3.2; PRESERVE and T2T)
 ACR/EULAR Boolean remission criteria [39]:
 Sustained Boolean remission (remission at the
last two time points, with remission defined as
tender joint count (TJC) ≤ 1, swollen joint count
(SJC) ≤ 1, C-reactive protein (CRP) ≤ 1 mg/dL,
and patient global assessment ≤ 1 on a 0–10
scale)
 Remission
 Nonremission
 CDAI remission criteria [40]:
 Sustained CDAI remission (remission at the last
two time points, with remission defined as CDAI
0.0–2.8)
 Remission
 LDA (CDAI > 2.8–10.0)
 Moderate disease activity (CDAI > 10.0–22.0;
PRESERVE and T2T)
For the PRIZE study, we did not include DAS28 LDA
at the end of period 1 because only patients who
achieved remission at the end of period 1 were allowed
to enter period 2. Additionally, we did not include CDAI
moderate disease activity for PRIZE because there were
no patients in this category at the end of period 1.
Then, the proportion of patients maintaining remission
or LDA (DAS28 and CDAI criteria only) in period 2 was
determined according to each response level in period 1.
Period 2 response (remission or LDA) was measured only
at the last time point in period 2 (PRESERVE: week 88,
PRIZE: week 91, T2T: week 52). Patients with remission
or LDA at the last time point in period 2 were considered
to have maintained that response following dose decrease
or withdrawal of etanercept. However, it is unknown
whether those patients were in remission or LDA at other
time points in period 2.
Demographic and baseline disease characteristics of
the patients in each study were categorized according
to the following DAS28 responses at the end of
period 1: sustained deep remission, deep remission,
sustained remission, remission, and LDA (LDA for
PRESERVE and T2T), and also according to the fol-
lowing CDAI responses at the end of period 1: sus-
tained remission, remission, LDA, and moderate
disease activity (MDA) (MDA for PRESERVE and
T2T).
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Statistical analyses
Trend in baseline characteristics among the period 1 re-
sponse categories (DAS28 or CDAI) was analyzed using
one-way analysis of variance for continuous variables
with response categories treated as ordered, and the
Cochran-Mantel-Haenszel (CMH) test of linear associ-
ation for categorical variables. The CMH test was also
used to evaluate the trend in proportion of responders
(i.e., remission or LDA) in period 2 among period 1 re-
sponders, using a last observation carried forward ap-
proach within period 2.
We conducted two additional analyses. We deter-
mined the proportion of patients with a normal value on
the Health Assessment Questionnaire (HAQ ≤ 0.5) at
the end of period 1 according to whether or not they
achieved sustained DAS28 deep remission at the end of
period 1. Finally, we conducted four stepwise predictor
analyses and a sensitivity analysis to determine the best
subset of significant predictors in maintaining DAS28 re-
mission in period 2. The predictors from period 1 base-
line that were included in the analyses were selected
because each of them had a significant relationship with
period 1 DAS28 response categories. In the first stepwise
analysis, the predictors included sustained deep remis-
sion, age in 10-year units, gender, HAQ ≤ 0.5, ESR
≤ upper limit of normal (ULN), body mass index (BMI
≤ 18.5, > 18.5 to ≤ 30, > 30), SJC = 0 out of 28, and TJC
= 0 out of 28. Additional stepwise predictor analyses
included the following predictors: study and period 2
treatment group and/or continuous rather than dichot-
omous BMI and SJC/TJC.
Results
Clinical response in period 1 and baseline characteristics
according to clinical response
This analysis includes 600, 598, and 594 patients in the
ACR/EULAR Boolean, CDAI, and DAS28 remission cri-
teria calculations, respectively, from the PRESERVE
study; 193, 192, and 192 patients, respectively, from the
PRIZE study; and 331 patients in all three remission cri-
teria calculations from the T2T study. This variability is
due to (1) five patients in PRESERVE with DAS28 values
> 3.2 at week 36 and one patient with a missing DAS28
value being excluded from the DAS28 analysis, (2) one
patient in PRIZE with DAS28 > 2.6 at week 52 being ex-
cluded from the DAS28 analysis, and (3) three patients
(two from PRESERVE and one from PRIZE) missing
component(s) required for calculating CDAI remission.
Table 2 presents the proportion of patients in each
DAS28 response category at the end of period 1, as well
as demographics and baseline disease characteristics ac-
cording to each DAS28 response at the end of period 1.
All three studies demonstrated a significant difference in
mean age according to response category, with younger
age being associated with a better DAS28 response in
period 1. Lower values for ESR, DAS28-ESR, and HAQ
were associated with a better response in PRESERVE
and T2T; as were lower values for TJC and CDAI, and a
lower proportion of females in T2T; lower BMI in
women in PRESERVE and PRIZE; and lower SJC in
PRIZE.
The proportion of patients in each CDAI response cat-
egory at the end of period 1 and demographics and base-
line disease characteristics according to each CDAI
response are presented in Additional file 1: Table S1. In
all three studies, younger age was associated with a bet-
ter clinical response. In the PRESERVE and PRIZE stud-
ies, prior treatment with a corticosteroid was associated
with a poorer clinical response, and higher baseline ESR,
lower TJC, lower SJC, and lower BMI in women were
associated with a better clinical response. In PRESERVE,
lower CDAI, physician’s global assessment, and HAQ
were each associated with a better clinical response, as
were positive laboratory results for rheumatoid factor
and anti-cyclic citrullinated peptide antibodies in PRIZE.
The proportion of patients achieving each ACR/
EULAR Boolean criteria response at the end of period 1
is provided in Additional file 1: Table S2.
Predictor analyses
All four stepwise predictor analyses and the sensitivity
analysis determined that at the end of period 1, the sig-
nificant predictors of period 2 DAS28 remission were
sustained deep remission, ESR ≤ULN, SJC = 0, and TJC
= 0. Since ESR is included in the DAS28 calculation, this
association is expected. Study and treatment group were
also determined to be significant predictors. Patients
who continued etanercept 50 mg were most likely to
have DAS28 remission at the end of period 2, followed
by patients who decreased the dose to 25mg, and lastly
by patients who discontinued etanercept. When SJC and
TJC were treated as continuous, they were found to be
significant as well. HAQ ≤ 0.5, age, gender, and BMI
were not significant predictors. The significant results
from one of the predictor analyses are presented in
Table 3.
Clinical response in period 2
PRESERVE study
Patients in the PRESERVE study demonstrated signifi-
cant remission response trends in period 2 for all three
measurement criteria in all treatment groups. Patients
who achieved DAS28 sustained deep remission in period
1 and then discontinued etanercept were more likely to
maintain DAS28 remission in period 2 (25/41, 61%) than
those who achieved deep remission (13/44, 30%), sus-
tained remission (10/34, 29%), remission (8/39, 21%), or
LDA (2/39, 5%), P < 0.001 for trend (Fig. 1a). These
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patients were also more likely to maintain DAS28 LDA
(31/41, 76%) than those who initially achieved deep re-
mission (16/44, 36%), sustained remission (14/34, 41%),
remission (18/39, 46%), or LDA (10/39, 26%), P < 0.001.
The patients who achieved sustained deep remission in
period 1 and then decreased the dose of etanercept to
25mg were more likely to maintain remission in period
2 (35/43, 81%) than those who achieved deep remission
(29/43, 67%), sustained remission (22/38, 58%), remis-
sion (20/36, 56%), or LDA (14/39, 36%), P < 0.001. The
response trend was not significant for maintenance of
LDA.
The patients who achieved sustained remission in
period 1 based on the ACR/EULAR Boolean criteria and
then discontinued etanercept were more likely to main-
tain remission (10/34, 29%) than those who achieved re-
mission (7/45, 16%) or did not achieve remission (4/119,
3%) in period 1, P < 0.001 (Fig. 1b). Patients who de-
creased the dose had a numerically greater response
than those who discontinued; the patients with sustained
remission in period 1 were more likely to maintain re-
mission (32/44, 73%) than those who achieved remission
(12/32, 38%) or did not achieve remission (23/125, 18%),
P < 0.001.
In the CDAI analysis, patients in all treatment groups
were more likely to maintain remission or LDA in
period 2 if they achieved sustained remission in period
1. Additionally, patients who decreased the dose of eta-
nercept had a numerically greater response than those
who discontinued etanercept (Fig. 1c). Of the patients
who achieved sustained remission in period 1 and then
discontinued etanercept, 7/23 (30%) and 19/23 (83%)
maintained remission and LDA, respectively, versus 4/33
(12%) and 16/33 (48%) who achieved remission, 11/129
(9%) and 70/129 (54%) who achieved LDA, and 0/11
(0%) and 2/11 (18%) who achieved moderate disease ac-
tivity, P < 0.01 for both. Of the patients who achieved
sustained remission in period 1 and then decreased the
dose of etanercept, 26/36 (72%) and 33/36 (92%) main-
tained remission and LDA, respectively, versus 15/30
(50%) and 24/30 (80%) who achieved remission, 23/127
(18%) and 105/127 (83%) who achieved LDA, and 0/8
(0%) and 2/8 (25%) who achieved moderate disease ac-
tivity, P < 0.001 for remission and P < 0.05 for LDA.
PRIZE study
Patients in the PRIZE study demonstrated significant re-
sponse trends for all treatment groups according to
ACR/EULAR Boolean criteria, and for two treatment
groups according to CDAI criteria, with no significant
response trends observed according to DAS28 criteria.
In the DAS28 analysis, the group that decreased the
dose of etanercept demonstrated a better response than
the groups that discontinued etanercept and discontin-
ued etanercept+methotrexate (MTX) (Fig. 2a).
In the ACR/EULAR Boolean remission criteria ana-
lysis, some of the sample sizes were small (Fig. 2b). In
the group that decreased the dose of etanercept, period
2 remission was maintained by 7/8 (88%) patients with
period 1 sustained remission, versus 3/11 (27%) with re-
mission and 7/44 (16%) without remission in period 1,
P < 0.01. In the group that discontinued etanercept, re-
mission was maintained by 6/9 (67%), 2/10 (20%), and
5/46 (11%), respectively, P < 0.001. In the group that dis-
continued etanercept+MTX, remission was maintained
by 8/13 (62%), 3/6 (50%), and 0/46 (0%), respectively,
P < 0.001.
Table 3 Subset of significant predictors of period 2 DAS28 remission
End of period 1 predictor Odds ratio (95% CI) P value
SJC28 = 0 vs > 0 2.1 (1.4, 3.0) < 0.001
TJC28 = 0 vs > 0 1.7 (1.2, 2.5) 0.003
Study 0.008
PRESERVE vs T2T 0.7 (0.4, 1.2)
PRIZE vs T2T 1.7 (0.8, 3.5)
Sustained deep remission vs not sustained remission 2.4 (1.5, 3.9) < 0.001
ESR≤ ULN vs > ULN 2.7 (1.5, 4.8) 0.001
Treatment < 0.001
ETN 25 mg +MTX vs PBO +MTX 2.7 (1.7, 4.3)
ETN 50 mg +MTX vs PBO +MTX 3.3 (2.1, 5.0)
MTX vs PBO 0.7 (0.3, 1.7)
The subset of significant predictors was determined using a stepwise model with the following “end of period 1” predictors: sustained deep remission vs not; age
in 10-year units; gender; body mass index ≤ 18.5, > 18.5 to ≤ 30, 30; HAQ ≤ 0.5 vs > 0.5; ESR ≤ ULN vs > ULN; SJC28 = 0 vs > 0; TJC28 = 0 vs > 0; study;
treatment group
CI confidence interval, ESR erythrocyte sedimentation rate, ETN etanercept, HAQ health assessment questionnaire, MTX methotrexate, PBO placebo, SJC28 swollen
joint count measured using 28 joints, TJC28 tender joint count measured using 28 joints, ULN upper limit of normal
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In the CDAI analysis, a significant response trend was
present for the group that decreased the dose of etaner-
cept and the group that discontinued etanercept+MTX
(Fig. 2c). In the dose reduction group, period 2 remis-
sion was maintained by 34/40 (85%) of patients with sus-
tained remission in period 1 versus 4/8 (50%) and 7/15
(47%) with remission and LDA, respectively, P < 0.01. In
the group that discontinued etanercept+MTX, period 2
remission was maintained by 16/31 (52%) with sustained
remission in period 1, versus 0/13 (0%) and 3/20 (15%)
with remission and LDA, respectively, P < 0.01.
T2T study
Patients in the T2T study demonstrated significant
response trends in period 2 across all measurement
criteria in all treatment groups, although in many
instances, the sample sizes were small. In most cases,
the patients who continued etanercept 50 mg in period 2
a
b
c
Fig. 1 Proportion of patients in the PRESERVE study maintaining remission or LDA in period 2, according to response category in period 1 for the
remission criteria of DAS28 (a), ACR/EULAR Boolean (b), and CDAI (c). ACR American College of Rheumatology, CDAI Clinical Disease Activity
Index, DAS28 Disease Activity Score in 28 joints, ETN50 etanercept 50mg, EULAR European League Against Rheumatism, LDA low disease activity,
MTX methotrexate, PBO placebo
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demonstrated higher rates of remission and LDA than
those who discontinued etanercept. For the group
that discontinued etanercept, DAS28 remission was
maintained in period 2 by 3/3 (100%) patients with
sustained deep remission in period 1 and by 6/15
(40%), 2/8 (25%), 7/35 (20%), and 4/107 (4%) patients
with deep remission, sustained remission, remission,
and LDA, respectively, P < 0.001 (Fig. 3a). DAS28
LDA was maintained by 3/3 (100%), 6/15 (40%), 2/8
(25%), 10/35 (29%), and 8/107 (7%) patients, respect-
ively, P < 0.001.
In the ACR/EULAR Boolean analysis, the proportion of
patients who discontinued etanercept and maintained re-
mission was 4/7 (57%), 9/29 (31%), and 4/132 (3%) of the
patients with sustained remission, remission, and nonre-
mission in period 1, respectively, P < 0.001 (Fig. 3b). In the
CDAI analysis, the proportion of patients who discontin-
ued etanercept and maintained remission was 2/6 (33%),
a
b
c
Fig. 2 Proportion of patients in the PRIZE study maintaining remission or LDA in period 2, according to response category in period 1 for the
remission criteria of DAS28 (a), ACR/EULAR Boolean (b), and CDAI (c). ACR American College of Rheumatology, CDAI Clinical Disease Activity
Index, DAS28 Disease Activity Score in 28 joints, ETN50 etanercept 50mg, EULAR European League Against Rheumatism, LDA low disease activity,
MTX methotrexate, PBO placebo
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7/18 (39%), 11/128 (9%), and 0/16 (0%) of the patients
with sustained remission, remission, LDA, and moderate
disease activity in period 1, respectively, P < 0.001; LDA
was maintained by 3/6 (50%), 13/18 (72%), 53/128 (41%),
and 3/16 (19%), P < 0.01 (Fig. 3c).
In all three studies, continuing etanercept 50 mg or de-
creasing the dose to 25mg resulted in a greater propor-
tion of patients maintaining remission or LDA than
discontinuing etanercept.
Sustained DAS28 deep remission and the Health
Assessment Questionnaire
The proportion of patients with a normal HAQ score at
the end of period 1 was significantly higher for those pa-
tients who achieved sustained DAS28 deep remission at
the end of period 1 than for those who did not, in all
three studies (Additional file 1: Figure S1). In PRE-
SERVE, 82.0% of patients with sustained DAS28 deep re-
mission had a HAQ score ≤ 0.5, compared with 59.2% of
a
b
c
Fig. 3 Proportion of patients in the T2T study maintaining remission or LDA in period 2, according to response category in period 1 for the remission
criteria of DAS28 (a), ACR/EULAR Boolean (b), and CDAI (c). ACR American College of Rheumatology, CDAI Clinical Disease Activity Index, csDMARDs
conventional synthetic disease-modifying antirheumatic drugs, DAS28 Disease Activity Score in 28 joints, ETN50 etanercept 50mg, EULAR European
League Against Rheumatism, LDA low disease activity, MTX methotrexate, PBO placebo
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patients who did not achieve sustained DAS28 deep re-
mission, P < 0.001. The corresponding values for PRIZE
were 94.0% vs 75.0%, P = 0.001, and for T2T, 91.7% vs
51.4%, P = 0.006.
Discussion
The results of this analysis demonstrate that overall, the
likelihood of patients maintaining remission or LDA fol-
lowing dose reduction or discontinuation of etanercept
follows a significant trend, with those initially achieving
sustained deep remission being the most likely to main-
tain a response, followed by those achieving deep remis-
sion and sustained remission. This was the case whether
remission was measured using DAS28 (except in
PRIZE), ACR/EULAR Boolean, or CDAI criteria. Add-
itionally, a greater proportion of patients maintained
LDA than remission.
It is of interest to note that most of the remission
trend results were similar across the studies, even
though the patient populations were different. The PRE-
SERVE and T2T studies represented an established RA
population; patients had a disease duration of approxi-
mately 7 to 8 years. Conversely, the PRIZE study repre-
sented an early RA population with a mean disease
duration of 6.5 months. The mean number of prior
csDMARDs was slightly higher in the PRESERVE and
T2T studies (1.3 for each) than in the PRIZE study (1.0),
likely owing to the shorter disease duration in PRIZE.
Patients in the PRESERVE and PRIZE studies were
bDMARD naïve; only one patient in T2T had a history
of bDMARD therapy.
In the PRIZE study, a relatively high proportion of pa-
tients achieved sustained deep remission in period 1
compared to the other levels of remission and compared
to the other two studies. This result may be related to
these patients having early disease, although the PRIZE
study also had the longest period of open-label etaner-
cept treatment. In this study only, the response trend ac-
cording to the DAS28 criteria was not significant,
suggesting that in patients with early disease, it may be
more appropriate to use the ACR/EULAR Boolean or
CDAI remission criteria than the DAS28.
In the HONOR and RRR trials, 80% and 71% of pa-
tients with DAS28 deep remission were able to maintain
LDA following discontinuation of adalimumab and
infliximab, respectively [29, 30]. In the current analysis,
the proportions of patients with DAS28 sustained deep
remission/deep remission in period 1 who maintained
LDA following discontinuation of etanercept were 76%/
36%, 75%/78%, and 100%/40% for PRESERVE, PRIZE,
and T2T, respectively. Many of these values are similar
to those reported in HONOR and RRR [29, 30].
For patients, improvement in functional disability is an
important aspect of RA treatment, because it affects
daily activities, the ability to work, and long-term mor-
bidity and mortality [41–43]. We found that the propor-
tion of patients with a normal HAQ score at the end of
period 1 was significantly higher for those patients who
achieved sustained DAS28 deep remission at the end of
period 1 than for those who did not, in all three studies.
These results are in line with a published study that
found that improvement in the HAQ score continues if
LDA or remission is achieved and sustained [44]. An-
other study determined through multivariate analyses
that having a lower HAQ score at the start of treatment
predicts 2-year sustained DAS28 remission [45]. In our
analysis, we did not find HAQ ≤ 0.5 to be among the
best subset of significant predictors in maintaining
DAS28 remission; however, lower baseline values for
HAQ were associated with a better period 1 DAS28 re-
sponse in PRESERVE and T2T, and a better CDAI re-
sponse in PRESERVE.
This study has several limitations. The data pertain to
etanercept and likely to other tumor necrosis factor
(TNF) inhibitors, but not to IL-6 or JAK inhibitors that
directly affect the acute-phase response and as a result,
may lead to unduly low DAS28 values. Further, the
patients included in this study had moderate or
moderate-to-severe RA disease activity, so these results
may not be applicable to patients with mild or low RA
disease activity; however, in these patients, bDMARDs
are rarely indicated or reimbursed. In the PRIZE and
T2T studies, the sample sizes were small for many of the
remission categories at the end of period 1; therefore,
the period 2 results need to be interpreted with caution.
Also, the duration of exposure to etanercept differed
among the three studies, and this is a variable that must
be considered when evaluating the results. Additionally,
we cannot draw conclusions regarding maintenance of
remission or LDA for periods longer than in these stud-
ies. Finally, caution should be exercised when generaliz-
ing these results to all patients, because the patients in
these clinical trials were selected based on strict inclu-
sion and exclusion criteria.
In future studies, it would be interesting to evaluate
whether differences between sustained deep remission,
deep remission, sustained remission, remission, and LDA
are noted on ultrasound. Studies have found that approxi-
mately 50–75% of patients with RA in clinical remission
still have active synovitis on ultrasound [46–51]. One study
that evaluated patients with deep clinical remission
(DAS28 ≤ 1.98) and remission (DAS28 ≤ 2.6 but > 1.98)
found that significantly fewer patients with deep remission
compared to remission had evidence of synovitis on ultra-
sound [51]. This is in line with using more stringent remis-
sion criteria, such as the ACR/EULAR Boolean definition,
which does not require definition of “deep” remission,
since, as also seen here, it already reflects deep remission.
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Conclusions
The results of this study add to the published evidence
that some patients can successfully decrease the dose or
discontinue bDMARD therapy [8–16]. In certain cases,
this may be desirable for the purposes of decreasing the
risk of adverse events and/or reducing costs. Although
the most appropriate patients and dose reduction strat-
egy remain unclear, this study found that sustained deep
remission, normal ESR, SJC = 0, and TJC = 0 at the end
of period 1 were significant predictors of maintaining
DAS28 remission after etanercept dose reduction or dis-
continuation. Additionally, our results suggest that clini-
cians should consider using a stringent definition of
disease control, such as sustained deep remission ac-
cording to DAS28, or sustained remission according to
CDAI/SDAI or ACR/EULAR Boolean criteria. Con-
trolled clinical studies evaluating the endpoints of sus-
tained and/or deep remission are needed.
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